Selection criteria
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement for reporting systematic reviews and meta-analyses
was applied to the methods of this study. Studies with the following
characteristics were considered eligible for this analysis: a) had a
randomized controlled design; b) included patients with prior myocardial
infarction and VT; c) studies with outcomes stratified by LVEF; d)
included patients that were randomized to first line VT ablation or a
control group based on medical therapy as an initial therapy; e)
patients were followed for an average duration of at least 12 months; f)
studies included survival-free from VT/VF and/or rates of appropriate
ICD therapies as their endpoints.